Should You Buy Cameco While It's Below $90?

Cameco has rallied materially (up ~63% YTD, ~251% over three years) as U.S. policy and demand drivers — notably data-center/AI-driven electricity growth and executive actions to accelerate nuclear deployment — boost prospects for uranium and reactor builds. The company owns stakes in high-grade assets (McArthur River 70%, Cigar Lake 55%, Key Lake mill 83%, Inkai 40%) and a 49% interest in Westinghouse, which is part of a partnership to deploy at least $80 billion of new Westinghouse AP1000 reactors in the U.S.; Bank of America raised its NAV and multiple on this basis. Cameco cut 2025 production guidance for McArthur River/Key Lake to 14–15m lbs U3O8 (Cameco share 9.8–10.5m) from 18m due to development delays, a shortfall Cantor Fitzgerald called immaterial, while the stock trades at a rich ~55x 2025 projected earnings with EPS forecast to reach $2.25 by 2028 (≈30% CAGR from 2025).

Analysis

Market structure: Winners are integrated, scale uranium producers and reactor OEMs — CCJ and Brookfield (BAM/BEP) — plus utilities with long-term offtake; losers are high-cost juniors and spot-levered ETFs if long-term contracting outpaces spot demand. The U.S. policy push (>$80B reactor program cited) materially increases structural demand for reactor services and contracted uranium over 5–10 years while short-term production hiccups (McArthur River freeze delays) tighten near-term spot supply.

Risk assessment: Key tail risks include a policy reversal or major nuclear incident, protracted McArthur River delays, or normalization of Russian/Kazakh flows that relieve supply tightness; any of these could erase >30–50% of CCJ’s implied upside. Immediate (days) volatility will track headlines on the U.S. strategic uranium reserve; medium term (3–12 months) will reflect 2025 production realizations; long term (3–7 years) depends on reactor award cadence and contract rollouts.

Trade implications: Given CCJ’s 55x forward earnings and share pullback to <$90, favor staged exposure: core long exposure to CCJ and Brookfield renewable/BAM for asymmetric payoff from Westinghouse upside, use defined‑risk option spreads to lever upside while capping loss, and underweight small-cap juniors and URA-style ETFs. Enter on policy-confirming catalysts (reserve >30M lbs or first AP1000 awards) and scale in on dips to $75 and $60; harvest gains if CCJ >$135 within 12–24 months.

Contrarian angles: The market may be underpricing execution risk and overpaying for growth — 55x implies flawless execution and fast EPS ramp to $2.25 by 2028. Historical uranium cycles (pre-Fukushima boom/bust) show long lead times and sharp mean reversion; unintended consequence: a Westinghouse-led build could centralize fuel contracting and mute commodity spot rallies, favoring reactor OEMs over miners.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in CCJ in three tranches: 40% at current price (<$90), 30% if CCJ < $75, and 30% if CCJ < $60; target hold 12–24 months and take profits if CCJ > $135 (≈50% gain) or cut to 0.5% if 2025 production/share guidance misses consensus by >15%.
• Buy a defined‑risk options spread to lever upside: purchase Jan 2027 CCJ 90C and sell Jan 2027 CCJ 150C (~1:1) sized to equal 1% portfolio risk; this limits max loss to paid premium while allowing >60% upside capture if reactor build-out and reserve policy materialize.
• Implement a relative value trade: go long CCJ (1.5% portfolio) and short URA (Global X Uranium ETF) sized dollar-neutral (1.0–1.2% portfolio) to express quality/scale over junior/speculative exposure; reassess after 90 days or after first U.S. reactor awards.
• Reduce aggregate exposure to small-cap uranium juniors and spot uranium ETFs by 50% and redeploy 1–2% into BAM/BEP (Brookfield platform) to capture Westinghouse OEM upside with lower execution risk; increase allocation by +1% within 30 days if U.S. strategic reserve announced ≥50M lbs.